76 Views | 40 Downloads
John Mascarenhas, MD, Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Pl, Box 1079, New York, NY 10029, Email: john.mascarenhas@mssm.edu
AC received a 2018 ASH HONORS grant from the American Society of Hematology. JM receives research funding paid to the institution from Incyte, Roche, PharmaEssentia, Novartis, CTI Biopharma, Janssen, Promedior, Kartos, and Celgene; is on the clinical trial steering committee and an advisory board member for Incyte, Celgene, Roche, and Constellation Pharmaceuticals. JG has received research funding paid to the institution from Incyte, Novartis, CTI Biopharma, Janssen, Promedior, Kartos, and Celgene; is on the clinical trial steering committee and/or an advisory board member for Incyte, Novartis, Celgene, and Kartos. RR has received consulting fees from Constellation, Incyte, Celgene, Promedior, CTI, Jazz Pharmaceuticals, Blueprint, Stemline; and research funding from Incyte, Constellation, and Stemline. ATG has received research funding paid to the institution from Incyte, Roche, CTI Biopharma, Imago Biosciences, and Celgene; is on the clinical trial steering committee and an advisory board member for CTI Biopharma, Pfizer, Parmassentia, and Apexx Oncology. GSH has received research support from Bayer, Merck, Incyte and Constellation; is on the scientific advisory board for Incyte, BMS, Celgene, Agios, and Jazz; has received grants from K12 CA087723 Paul Calabresi Award, ASH-AMFDP, and Sanchez-Ferguson Award. EFW has received research funding from Incyte Corporation, Blueprint Medicine, and Sierra Oncology for clinical trials. The remaining authors have stated that they have no conflicts of interest.